QURE Stock Recent News

~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~

Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. BOSTON and INDIANAPOLIS , July 1, 2024 /PRNewswire/ -- Genezen, a best-in-class gene therapy CDMO, today announced an agreement to acquire uniQure's (Nasdaq: QURE) commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.

UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.

UniQure (QURE) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.02 per share a year ago.

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

uniQure said it is cutting back 28% of its workforce. The company is discontinuing much of its pipeline to focus on more promising therapies.

Gene therapy-focused biotechnology firm uniQure announced it is slashing more than half of its research and technology projects as part of a strategic reorganization aimed at reducing its operating expenses while advancing a selection of its clinical-stage programs to proof-of-concept.  The company said it will no longer be investing in AMT-210 for the treatment of Parkinson's disease and multiple other undisclosed programs.

UniQure N.V. QURE, -4.74%, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it's planning a strategic overhaul that will cut 28% of its workforce as it strives to cut costs and advance several clinical-stage programs.

The Food and Drug Administration has cleared uniQure's application for an epilepsy therapy. The company grew revenue in the second quarter by 380%, year over year.

As a rule of thumb, you should avoid targeting cheap securities, However, exceptions can always be made, particularly for these tantalizing stocks under $10 to buy. To be sure, the cheap ideas in the capital market attract much attention.